Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + capecitabine for advanced hepatocellular carcinoma with Child-Pugh B cirrhosis
NL-OMON32482Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and capecitabine in hepatocellular carcinoma (HCC), sponsored by Leiden University Medical Center. Primary endpoints: Progression-free survival at 6 months, Circulating microparticles and 2 more. Started Jul 2009; status: recruiting.
02
Drugs
everolimuscapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON32482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32482.